The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

KU ASCO 2019: Update on CLL Preferred Therapy - Venetoclax + Obinutuzumab

944 views
August 19, 2019
Comments 0
Login to view comments. Click here to Login